雷贝拉唑的抑酸活性对提高胃癌化疗效果的临床研究  

Clinical study of the anti- acid activity of rabeprazole in improving the chemotherapy of gastric cancer

作　　者：钟皎[1] 孙清[2] 

机构地区：[1]南京医科大学附属无锡第二医院药剂科,江苏无锡214002 [2]南京医科大学附属无锡第二医院肿瘤科,江苏无锡214002

出　　处：《中国临床药理学杂志》2015年第19期1919-1921,共3页The Chinese Journal of Clinical Pharmacology

基　　金：无锡市科技发展指导性计划(社会发展)基金资助项目(CSZ00N1138)

摘　　要：目的探讨雷贝拉唑的抑酸活性对提高胃癌化疗的效果以及其最佳给药时间。方法将30例胃癌患者随机分为对照组、试验A组和试验B组,每组10例。对照组予以口服2000 mg·m^-2·d^-1卡培他滨,每日2次,第1-14天加静脉滴注130 mg·m^-2·d^-1奥沙利铂,第1天;试验A组在对照组的基础上,加用口服雷贝拉唑20 mg,每天1次,第1-14天;试验B组在对照组的基础上,加用口服雷贝拉唑20 mg,每天1次,第-7-13天（即在化疗药开始前7天即开始使用）。3组患者均接受2个周期的治疗,每个周期21 d。比较3组患者治疗后的临床疗效和不良反应发生率。结果对照组、试验A组、试验B组的有效率分别为25.00%,33.33%和30.00%,疾病控制率分别为62.50%、77.78%和70.00%,组间比较差异无统计学意义（P〉0.05）,但试验组的有效率和疾病控制率较对照组呈增高的趋势。治疗期间,3组患者的主要不良反应为消化道反应、血液学毒性和手足综合征,但组间比较差异无统计学意义（P〉0.05）。试验A组与试验B组的雷贝拉唑血药浓度比较差异无统计学意义（P〉0.05）。结论卡培他滨联合奥沙利铂的临床疗效较好,不良反应较轻,雷贝拉唑提前1 d给药即可达稳态。Objective To investigate whether rabeprazole could increase the sensitivity of chemotherapy on gastric cancer and to evaluate the optimal time of drug administration. Methods Thirty patients with gastric cancer were enrolled into the study and divided into three groups： control group and treatment group A and B,10 patients in each group. Patients in control group were received： capecitabine 2000 mg·m^-2·d^-1divide to twice a day,oral on day 1- 14,oxaliplatin 130 mg·m^-2·d^-1ivgtt on day 1. The treatment group A and B administrate rabeprazole 20 mg qd on day 1- 14 and day- 7- 13,respectively,on the basis of control group＇s treatment. Twenty- one days was one cycle,2 cycles for each group. Clinical efficacy and adverse drug reactions after two cycles in three groups were evaluated. Results The response rate of the control group,treatment group A and treatment group B were 25. 00%,33. 33%and 30. 00% respectively, the disease control rate were 62. 50%,77. 78% and 70. 00% respectively,there were no significat difference among three groups on the effect of chemotherapy. The response rate and the disease control rate of the treatment group were higher than those ofthe control group. The main adverse drug reactions during the treatment were gastrointestinal reaction,hematological toxicity and hand foot syndrome,and there was no statistic difference among three groups（ P〉0. 05）. The plasma concentration of rabeprazole between two treatment groups was no statistic difference（ P〉0. 05）. Conclusion The clinical icacy of this chemotherapy（ capecitabine ＋ oxaliplatin） is better and the adverse drug reactions are less. Plasma concentration of rabeprazole could reach steady state in one day after drug administration.

关 键 词：雷贝拉唑 胃癌 抑酸活性 Warburg效应 

分 类 号：R975[医药卫生—药品] R979.1[医药卫生—药学]